Schema-Root.org logo

 

  cross-referenced news and research resources about

 Johnson & Johnson

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Wed. May 2, 2018

-
Johnson & Johnson Wins Appeal to Overturn $151 Million Hip Implant Verdict ... (Reuters) - Johnson & Johnson on Wednesday secured a favorable U.S. appellate court ruling, overturning a verdict that had awarded $151 million to five people who blamed injuries they suffered on the company's Pinnacle ...
Johnson & Johnson (NYSE:JNJ) delivered a less impressive 2.07% ROE over the past year, compared to the 11.33% return generated by its industry. Though JNJ's recent performance is underwhelming, it is useful to understand what ROE is made up of and how it should be interpreted. Knowing these ...

J&J DePuy unit lawyer John Beisner commented that the ruling correctly identified errors in the trial that made it “impossible for defendants to get a fair trial.” In March, An Indiana jury hit Johnson & Johnson subsidiary Ethicon with a $35 million verdict in a product liability lawsuit brought over its Prolift pelvic ...
Rumors of a buyout for Geron (NASDAQ:GERN) have been around for a couple years now, but in the last several months the topic of a buyout has become a hot topic for many Geron investors. Last week I presented a logical argument why GERN is a great investment in terms of risk vs. reward. In this article ...
PARIS and NEW YORK, Apr. 24 /CSRwire/ – EcoVadis, the leader in business sustainability ratings for global supply chains, expands its support of the Sustainable Purchasing Leadership Council (SPLC) to include gold-level sponsorship of the 2018 SPLC Summit and the SPLC webinar series, as well as ...
The investment has seen a significant return for the company, becoming one of its fastest-growing platforms. Johnson & Johnson only began investing in eye surgery two years ago after announcing it would acquire Abbot Medical Optics for $4.3 billion. The acquisition put products covering cataract surgery, ...

JNJ reported solid Q1 results but the stock is off over 3% post-earnings. The company expects single digit organic revenue growth for 2018. Its EPS is expected to grow around 11%. JNJ trades at 15x forward earnings, but 11x to 12x could be justified based on traditional earnings fundamentals. As the Fed ...
There are many stocks that are beloved by income focused investors, one group of those are the so called Dividend Aristocrats — companies that have raised their payout for at least 25 years in a row. An even more elite group of companies are the Dividend Kings, companies that have raised their dividend ...
Johnson & Johnson (NYSE:JNJ) recently reported that its revenue soared 12.6% to $20 billion in the first quarter. However, that revenue growth rate comes with an asterisk. In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes is joined by Todd Campbell to explain. Plus, the ...
Johnson & Johnson (NYSE:JNJ), a staple in investor portfolios, has plenty of news for us to digest in its first-quarter earnings release. In this episode of The Motley Fool's Industry Focus: Healthcare, host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to explain how Johnson & Johnson is ...
Johnson & Johnson CFO: Pharma business continues 'stellar' results. 6:50 AM ET Tue, 17 April 2018. Dominic Caruso, Johnson & Johnson CFO, and CNBC's Meg Tirrell, discuss the company's quarterly earnings which beat Street estimates on the top and bottom line. Watch CNBC Live TV ...
Johnson & Johnson topped Wall Street's first-quarter earnings and revenue expectations, fueled by strong pharmaceutical growth. Sales of some of its drugs boomed, offsetting weaknesses for some of its treatments that are facing competitive pressure. Vision care sales, including contacts and surgical ...
How does Johnson & Johnson measure up in the three areas of growth, income, and value? Pretty well. Johnson & Johnson hasn't achieved the rate of earnings growth or stock gains that AbbVie has in recent years. Yet the company appears to be positioned for future growth thanks to acquisitions and a ...
Shares of Johnson & Johnson (JNJ) ended the trading day Friday at $128.15, representing a move of 0.55%, or $0.7 per share, on volume of 6.12 million shares. Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health ...
Johnson & Johnson has become the latest advertiser to pull its ads from Laura Ingraham's Fox News show. The company confirmed to The Hill on Thursday that it would no longer be advertising on "The Ingraham Angle." Johnson & Johnson said that it “will pull advertising from Ms. Ingraham's show” in a ...
Johnson & Johnson has pledged a $1 million donation to the New Brunswick-based State Theatre, another move in a long-term relationship with the theatre and surrounding city. Johnson & Johnson is one of the State Theatre's current partners, according to the theatre's website. Scott Fergang, board chair ...
NEW BRUNSWICK, NJ: WPP and Omnicom Group have shuffled their agency lineups for client Johnson & Johnson. After a review, both holding companies have created separate networks dedicated to J&J to make the agency model more flexible, integrated, and cost-efficient, with the groups further ...

Johnson & Johnson (NYSE:JNJ) has incurred a 12% correction during the last two months. Nevertheless, most of its shareholders have a long-term perspective and thus hold the stock for its reliable and growing dividend. Therefore, as the company is expected to raise its dividend next month, the big ...
In my view, the case for buying Johnson & Johnson stock is stronger than the case against it. Falling sales for Remicade will no doubt continue to hurt J&J, but the company has a good plan for growth despite the headwinds. While it's true that there are other stocks that can claim better growth prospects or ...
Johnson & Johnson operates in three separate industries: Consumer health products, medical devices, and pharmaceuticals. This business model means that Johnson & Johnson's revenue stream is well diversified. The company is not too dependent on a positive growth outlook in one of its segments, ...
Johnson & Johnson JNJ, +0.55% said Friday it has received a binding offer from Platinum Equity to acquire its LifeScan business for about $2.1 billion. LifeScan is a blood glucose monitoring system with 2017 revenue of about $1.5 billion. If the offer is accepted by a June 15 deadline, the company expects ...
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace innovation—bringing ideas, products and services to life to advance the health and well-being of people around the world. We believe in collaboration, and that has led to breakthrough after breakthrough, from ...
“The government is currently in talks with Johnson & Johnson and Mylan,” a senior official said, referring to procurement prices of bedaquiline and delamanid. The official declined to specify the options discussed. He said negotiations are going on and the government has not made a final decision on the ...
Joaquin Duato is Executive Vice President, also Worldwide Chairman of Pharmaceuticals. Thank you for joining us. We have Joe Wolk from the Investor Relations team; and then, Paul Choi from my team. So, we're just going to do a nice chat fireside chat here. But, I think, Joe, you wanted to read ...
The Sell for Johnson & Johnson (JNJ) this week is based on the most current relative pricing of its shares and stock market ratings. The rationale for Johnson & Johnson Co's (NYSE:JNJ) Sell recommendation is grounded on a mathematical computation of risk/reward that is average, an analytical score that ...
Some pharmaceutical companies might worry when sales for a top-selling drug fall by $650 million year over year. Not Johnson & Johnson (NYSE: JNJ). Even though the company's top product, autoimmune-disease treatment Remicade, posted revenue in 2017 that was 9% lower than the prior year, J&J ...
This article will take a look at two healthcare giants, Johnson & Johnson (JNJ) and Pfizer (PFE). Both offer an attractive combination of dividend yield, dividend growth potential and total return potential. Johnson & Johnson has a particularly long history of dividend increases. It is a Dividend Aristocrat, ...
Okay. We're going to get started here. I'm Josh Jennings, Medical Device Analyst at Cowen and we're fortunate that Johnson & Johnson who's going to be very flexible despite the weather challenges and travel, and thanks to technology we're able to have a fireside chat remotely. So we're very pleased to ...
That is why a large corporation such as Johnson & Johnson Inc. seeks to foster innovation in its owns ranks, as well as outside of them. Consider JLABS, the incubator that Johnson & Johnson (NYSE: J&J) launched in 2012. The New Jersey-based health care conglomerate invites startups into its offices ...
But that's certainly not the case at Johnson & Johnson, explained CEO Alex Gorsky at the CECP's CEO Investor Forum in February. The forum was convened to discuss how CEOs and investors can have constructive dialogue around creating long-term value that benefits customers, employees, ...
Moving into health care is an appropriate move as we enter the last part of this expansion. JNJ posted solid topline numbers last year. Johnson & Johnson (JNJ) is the largest major drug manufacturer, with a market cap of $355 billion. It is also expensive: out of 28 major drug companies, it has the 9th ...
Johnson & Johnson reported better than expected Q1 2018 results. The corporate signals have been mixed with some positive messages related to Pharmaceutical Division but still unexciting outlooks for the Consumer Healthcare and Medical Devices Divisions. Despite the recent de-rating from 19x to ...
Johnson & Johnson posts solid results, although domestic growth is underwhelming. This performance is not strong enough as a multi-year momentum run has pushed up expectations among investors. Following a recent $20 pullback from the highs, the valuation is becoming more appealing, although I ...
Following is the transcript of a First On CNBC interview with Chairman & CEO of Johnson & Johnson, Alex Gorsky at the China Development Forum in Beijing. The interview was broadcast on CNBC on 27 March 2018. All references must be sourced to a "CNBC Interview'. Interviewed by CNBC's Martin ...
Johnson & Johnson (JNJ) holds a leadership position across multiple healthcare segments, including pharmaceuticals, medical devices, and over-the-counter consumer products. This helps JNJ consistently create impressive free cash flow, which has allowed the company to grow its dividend for over 50 ...
Johnson & Johnson (NYSE: JNJ) has grabbed attention from the analysts when it experienced a change of 0.04% in the last trading session to close at $132.07. A total of 6,664,372 shares exchanged hands during the intra-day trade contrast with its average trading volume of 7.53M shares, while its relative ...
Shares of Johnson & Johnson (JNJ) ended the trading day Monday at $132.07, representing a move of 0.68%, or $0.89 per share, on volume of 6.65 million shares. Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the ...
The retailer and the Johnson & Johnson allergy medication will be woven into the content of the musical-competition program, according to two people familiar with the matter, playing roles similar to the ones filled by big advertisers like Coke, Ford Motor and AT&T when “Idol” enjoyed a much-ballyhooed ...
Dear Mr. Berko: I bought 300 shares of Johnson & Johnson on your recommendation at $106 in April and have a 23-point profit. I bought it for the long term, and as you advised, I used Charles Schwab, which saved me a fortune on commissions. I paid about $7 in commission for the 300 shares and have ...
New data from a Phase 3 clinical trial, VOYAGE 2, evaluating Johnson & Johnson (JNJ +0.9%) unit Janssen Pharmaceuticals' TREMFYA (guselkumab) in patients with moderate-to-severe plaque psoriasis showed a durable treatment effect. The results will be presented tomorrow at the American Academy ...
Dear Mr. Berko: I bought 300 shares of Johnson & Johnson on your recommendation at $106 in April 2017 and have a 23-point profit. I bought it for the long term, and as you advised, I used Charles Schwab, which saved me a fortune on commissions. I paid about $7 in commission for the 300 shares and ...
Just after New Year's, in an announcement that was easy to overlook in the post-holiday haze, Johnson & Johnson's Janssen Pharmaceutical celebrated an historic FDA approval. The agency cleared new label language for the company's 9-year-old schizophrenia treatment, Invega Sustenna, stating that ...
In mid-November 2017, I wrote an article titled, “Johnson & Johnson: Does This Dividend Giant Still Offer Value?” This piece discussed why I viewed Johnson & Johnson (JNJ) as overvalued at the time due to the fact the price appreciation was far outpacing the earnings growth. At the time of the previous ...
We set out to verify if the below Facebook post, claiming that the baby shampoo made by Johnson and Johnson is poisoning your child, is toxic, and causes cancer. draft. (Photo: WKYC). The post has been shared over 800 times. Since January 17, other similar posts have also popped up on Facebook.
Johnson & Johnson (JNJ) was reviewed at the end of January where I wrote, "Bottom line: Tuesday is starting with many stocks in the red. JNJ could get pressured to break the 50-day average line and support around $140. Traders should consider raising stop loss protection to a close below $135.
Crucial on that committee has been the “Johnson & Johnson” junior guard duo of Jala Johnson and Kailah Johnson, who despite many assumptions to the contrary over the years are not twin sisters or even related to one another. “They're our primary ball-handlers and they make a ton of our decisions on ...
Johnson & Johnson isn't just a big pharma; it's a big consumer healthcare and big medical device company, too. These other two business segments have generated only modest growth for the healthcare giant recently, though. J&J's pharmaceutical business is where the company makes nearly half of its ...
Johnson & Johnson logo Credit Suisse Group set a $154.00 price objective on Johnson & Johnson (NYSE:JNJ) in a report published on Monday, January 22nd. The firm currently has a hold rating on the stock. JNJ has been the topic of a number of other research reports. Cowen reiterated an outperform ...
Being in a sector and an industry group that are ranked above average in attractiveness, Johnson & Johnson Co (NYSE:JNJ) Buy recommendation is all the more notable. Factors in this recommendation include a ranking in the company's industry group that is in the top half, a ranking in its sector group that ...
While the company is still strong, competition in the pharmaceutical sector as well as litigation settlements are potential risk factors. My yield target to invest further in this stock would be 3%. At that yield, the stock would need to trade at $112 given the current dividend payout. I am remaining long this stock, ...


 

news and opinion


 


 


 


 


schema-root.org

   consumer
     johnson & johnson
       subsidiaries

consumer corporations:
     avon products
     beverages
     candy
     chiquita
     clothing
     coca‑cola
     del monte
     dole
     electronics
     entertainment
     estee lauder
     fast food
     foods
     gap
     gillette
     johnson & johnson
     kellogg
     kraft foods
     nestle
     pepsico
     rite aid
     starbucks
     united brands
     wal‑mart